Nanosonics: Recommendation change to Hold

About the author:

Author name:

By Scott Power

Job title:

Senior Analyst

Date posted:

05 May 2023, 6:30 AM

Sectors Covered:

Healthcare, Life Sciences

• Nanosonics' (ASX:NAN) share price has gone through our target price and as a result we have moved our recommendation back to Hold (from Add).
• The key share price determinant in the next 6 months is the commercial launch of the CORIS® in limited jurisdictions.
• We have made no changes to forecasts and note that consensus is in a tight range for FY23 and FY24. Our target price remains unchanged. We will look for a better entry point around A$5.00.

Find out more

If you would like more information, please contact your adviser or nearest Morgans office. 

Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.